SQZ Biotechnologies Revenue 2020-2021 | SQZ

SQZ Biotechnologies revenue from 2020 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
SQZ Biotechnologies Annual Revenue
(Millions of US $)
2020 $21
2019 $20
SQZ Biotechnologies Quarterly Revenue
(Millions of US $)
2021-09-30 $5
2021-06-30 $5
2021-03-31 $5
2020-12-31 $2
2020-09-30 $6
2020-06-30 $6
2020-03-31 $6
2019-09-30 $4
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.203B $0.021B
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.345B 9.06
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.301B 19.14
Biohaven Pharmaceutical Holding (BHVN) United States $7.598B 0.00
Emergent Biosolutions (EBS) United States $2.503B 9.00
Arcus Biosciences (RCUS) United States $2.274B 0.00
Myovant Sciences (MYOV) United Kingdom $1.296B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.081B 0.00
Zymeworks (ZYME) Canada $0.538B 0.00
Ambrx Biopharma (AMAM) United States $0.201B 0.00
Enzo Biochem (ENZ) United States $0.155B 20.00